Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient

Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient

Abstract Background The FOLFOX regimen, i.e., folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers. Despite the concomitant improvements in response rate, duration of response and patient survival, reports of serious toxic...

Full description

Bibliographic Details
Main Authors: Annick De Weerdt, Amélie Dendooven, Annemie Snoeckx, Jan Pen, Martin Lammens, Philippe G. Jorens
Format: Article
Language:English
Published: BMC 2017-08-01
Series:BMC Cancer
Subjects:
FOLFOX
Oxaliplatin toxicity
Chemotherapy lung
Interstitial lung disease
Interstitial pneumonia
Drug induced pulmonary toxicity
Online Access:http://link.springer.com/article/10.1186/s12885-017-3576-y

Internet

http://link.springer.com/article/10.1186/s12885-017-3576-y

Similar Items